Welcome initiative
The decision taken recently by the editors of 11 Indian biomedical journals to publish only the results of human clinical trials that have been registered is laudable, considering that India has become one of the most favoured countries for conducting such trials and that more and more papers are published in Indian journals. The move is particularly significant in the context of the disturbing tendency of pharmaceutical companies to manipulate the results of human clinical trials for securing publication and drug approval.
Related Content
- Work Programme For The High-Level Champions And The Marrakech Partnership For Global Climate Action For 2020–2021
- With Carbon Dioxide Concentrations Nearing New Highs, 2020 Will Be ‘Make It or Break It Year’ for Climate Action, Secretary-General Warns
- The role of plug-in electric vehicles to improve fuel economy
- National action plan for egg & poultry-2022 for doubling farmers’ income by 2022
- Feedback to NITI Aayog on draft National Energy Policy (NEP)- July 2017
- US welcomes India's International Solar Alliance initiative on solar energy